Kebilidi (eladocagene exuparvovec-tneq) - Medicare Advantage

This policy covers Kebilidi (eladocagene exuparvovec‑tneq), a one‑time gene therapy administered via stereotactic neurosurgery (four intraputaminal infusions) for treatment of aromatic L‑amino acid decarboxylase (AADC) deficiency. Coverage is limited to pediatric patients 16 months through 10 years with confirmed biallelic DDC mutations, subject to Medicare "reasonable and necessary" criteria, single‑lifetime dosing, and excludes patients who are pregnant, breastfeeding, lack skull maturity, or are unwilling/unable to meet contraception or other procedural requirements.

"No documentation requirements are specified in the provided excerpt."

Sign up to see full coverage criteria, indications, and limitations.